Innogest Capital

Type

Venture Capital

Status

Active

Location

Milan, Italy

Total investments

67

Average round size

7M

Portfolio companies

43

Rounds per year

3.72

Lead investments

15

Follow on index

0.36

Exits

6

Stages of investment
Early Stage Venture
Areas of investment
BiotechnologyE-CommerceMobileHealth CareHospitalMedical DeviceMedicalFashionSustainabilityRecycling

Summary

Innogest Capital appeared to be the VC, which was created in 2006. The company was established in Europe in Italy. The main department of described VC is located in the Milan.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Innogest Capital, startups are often financed by Digital Magics, Italian Angels for Growth, Atlante Ventures. The meaningful sponsors for the fund in investment in the same round are Invitalia Ventures, Ysios Capital, Atlante Ventures. In the next rounds fund is usually obtained by TLcom Capital Partners, Ysios Capital, Tribeca Venture Partners.

The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 3 or 5+ of the founder, the probability for it to get the investment is little. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Italy. Among the most popular portfolio startups of the fund, we may highlight CornerJob, Cascaad (CircleMe), sardex.net. Among the most successful fund investment fields, there are Apps, Medical.

This organization was formed by Claudio Giuliano, Marco Pinciroli. Besides them, we counted 6 critical employees of this fund in our database.

The fund is generally included in 2-6 deals every year. The important activity for fund was in 2016. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2013. This Innogest Capital works on 22 percentage points less the average amount of lead investments comparing to the other organizations. Speaking about the real fund results, this VC is 20 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 5 - 10 millions dollars.

Show more

Investor highlights

Industry focus
Medtech
Stage focus
Series ASeries B

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
EUR 85000000
Fund raised date
2015-09-21

Analytics

Total investments
67
Lead investments
15
Exits
6
Rounds per year
3.72
Follow on index
0.36
Investments by industry
  • Health Care (19)
  • E-Commerce (13)
  • Medical (12)
  • Medical Device (12)
  • Biotechnology (12)
  • Show 86 more
Investments by region
  • Italy (50)
  • Spain (6)
  • United States (6)
  • Israel (1)
  • Switzerland (2)
  • Show 1 more
Peak activity year
2016

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
12
Avg. valuation at time of investment
680K
Group Appearance index
0.58
Avg. company exit year
6

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
BeeTV 17 May 2011 Software, iOS, Video on Demand Late Stage Venture 1M Italy, Milan, Lombardy
Erydel 01 Jul 2013 Biotechnology, Health Care, Pharmaceutical Early Stage Venture 17M Molise, Campobasso, Italy

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.